Companies › ONL Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ONL1204 Ophthalmic Solution Fragment apoptosis stimulator (FAS) receptor inhibitor | FAS | Phase 2 | Geographic Atrophy (GA) | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06659445 | ONL1204 Ophthalmic Solution | Phase 2 | Geographic Atrophy (GA) | Ophthalmology | Nov 2028 |
–
Qlaris Bio Aperta Biosciences Jiangsu Jingze Biopharmaceutical BioTheraVision Vantage Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.